SLC5A2 and kidney disorder: In the international CREDENCE trial on 4401 patients with a history of type-2 diabetes and kidney disease, the administration of the SGLT2 inhibitor canagliflozin resulted in fewer instances of both kidney failure and cardiovascular events compared to the placebo group during a median follow-up period of 2.62 years [16].